ConductScience.org, home

Paper42428494

Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.

Cao Z and 4 others. Front Pharmacol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies. Papers, record 42428494. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42428494

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.
PubMed
Journal
Front Pharmacol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cao ZZhanhong
2Zhang CChen
3Yang XXiaofan
4Shen YYue
5Bai YYuxin

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References214

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129378199Iron-induced oxidative stress stimulates osteoclast differentiation via NF-κB signaling pathway in mouse model.Metabolism2018https://conductscience.org/library/papers/29378199PubMed
231949885Curculigoside Protects against Excess-Iron-Induced Bone Loss by Attenuating Akt-FoxO1-Dependent Oxidative Damage to Mice and Osteoblastic MC3T3-E1 Cells.Oxid Med Cell Longev2019https://conductscience.org/library/papers/31949885PubMed
341551515The role of ferroptosis in osteoporosis: from pathogenic mechanisms to natural product-driven therapeutic innovations.Front Med (Lausanne)2025https://conductscience.org/library/papers/41551515PubMed
435863612Promising traditional Chinese medicine for the treatment of cholestatic liver disease process (cholestasis, hepatitis, liver fibrosis, liver cirrhosis).J Ethnopharmacol2022https://conductscience.org/library/papers/35863612PubMed
540515876Ferroptosis: Disease Associations and Therapeutic Target Exploration.J Mol Neurosci2025https://conductscience.org/library/papers/40515876PubMed
641003973Salidroside and inflammation-linked disorders: integrative insights into the pharmacological effects and mechanistic targets.Inflammopharmacology2025https://conductscience.org/library/papers/41003973PubMed
741036508Forsythiaside A Suppresses Ferroptosis and Mitigates Type 2 Diabetes Osteoporosis Through the NRF2/GPX4 Axis.Food Sci Nutr2025https://conductscience.org/library/papers/41036508PubMed
838569557A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis.Cell Metab2024https://conductscience.org/library/papers/38569557PubMed
941115354Salidroside alleviates senile osteoporosis in SAMP8 mice by inhibiting the ferroptosis of bone marrow stromal cells via PI3K/AKT/mTOR signaling pathway.Int Immunopharmacol2025https://conductscience.org/library/papers/41115354PubMed
1038081572Niacin treatment prevents bone loss in iron overload osteoporotic rats via activation of SIRT1 signaling pathway.Chem Biol Interact2024https://conductscience.org/library/papers/38081572PubMed
1139823248Aucubin Promotes BMSCs Proliferation and Differentiation of Postmenopausal Osteoporosis Patients by Regulating Ferroptosis and BMP2 Signalling.J Cell Mol Med2025https://conductscience.org/library/papers/39823248PubMed
1238142661Exploring the boost of steaming with wine on Ligustri Lucidi Fructus in treating postmenopausal osteoporosis based on superior "multi-component structure" and iron/bone metabolism coregulation.Phytomedicine2024https://conductscience.org/library/papers/38142661PubMed
1332065376Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review.Adv Ther2020https://conductscience.org/library/papers/32065376PubMed
1434360948The Development of Molecular Biology of Osteoporosis.Int J Mol Sci2021https://conductscience.org/library/papers/34360948PubMed
1535713852Astragalus polysaccharide: a review of its immunomodulatory effect.Arch Pharm Res2022https://conductscience.org/library/papers/35713852PubMed
1635638167Iron overload-induced ferroptosis of osteoblasts inhibits osteogenesis and promotes osteoporosis: An in vitro and in vivo study.IUBMB Life2022https://conductscience.org/library/papers/35638167PubMed
1735508203Molecular Mechanisms of Iron and Heme Metabolism.Annu Rev Nutr2022https://conductscience.org/library/papers/35508203PubMed
1840245968Qing'e Pill rectifies bone homeostasis imbalance in diabetic osteoporosis via the AGE/RAGE pathway: A network pharmacology analysis and multi-omics validation.J Ethnopharmacol2025https://conductscience.org/library/papers/40245968PubMed
1940416706Ferroptosis: New Strategies for Clinical Treatment of Rheumatoid Arthritis.J Inflamm Res2025https://conductscience.org/library/papers/40416706PubMed
2040488210Picroside II regulates the YY1/TGFβ1 axis by inhibiting osteoblast ferroptosis to alleviate symptoms of postmenopausal osteoporosis.Cytotechnology2025https://conductscience.org/library/papers/40488210PubMed

See all 214 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42428494

GET https://conductscience.org/api/papers/v1/42428494/references?page=2